Prosthetic joint infection: Difference between revisions
From IDWiki
No edit summary |
(→) |
||
| Line 19: | Line 19: | ||
*Bacteria grown on the prosthesis in a [[biofilm]], making it resistant to medical management |
*Bacteria grown on the prosthesis in a [[biofilm]], making it resistant to medical management |
||
| − | == |
+ | ==Clinical Manifestations== |
| − | * |
+ | *Most commonly occur within the 3 months after arthroplasty (early); 70% within the first two years |
==Management== |
==Management== |
||
| Line 48: | Line 48: | ||
!Chronic Suppressive Thearpy |
!Chronic Suppressive Thearpy |
||
|- |
|- |
||
| − | |debridement and retention |
+ | | rowspan="6" |debridement and retention |
| − | |[[Staphylococcus species]] |
+ | | rowspan="5" |[[Staphylococcus species]] |
|knee |
|knee |
||
| − | |2-6 weeks |
+ | | rowspan="5" |2-6 weeks |
|6 months |
|6 months |
||
| − | |yes; 4-6 weeks IV if not given |
+ | | rowspan="5" |yes; 4-6 weeks IV if not given |
|± |
|± |
||
|- |
|- |
||
| − | |debridement and retention |
||
| − | |[[Staphylococcus species]] |
||
|hip |
|hip |
||
| + | | rowspan="4" |3 months |
||
| − | |2-6 weeks |
||
| − | |3 months |
||
| − | |yes; 4-6 weeks IV if not given |
||
|± |
|± |
||
|- |
|- |
||
| − | |debridement and retention |
||
| − | |[[Staphylococcus species]] |
||
|elbow |
|elbow |
||
| − | |2-6 weeks |
||
| − | |3 months |
||
| − | |yes; 4-6 weeks IV if not given |
||
|± |
|± |
||
|- |
|- |
||
| − | |debridement and retention |
||
| − | |[[Staphylococcus species]] |
||
|shoulder |
|shoulder |
||
| − | |2-6 weeks |
||
| − | |3 months |
||
| − | |yes; 4-6 weeks IV if not given |
||
|± |
|± |
||
|- |
|- |
||
| − | |debridement and retention |
||
| − | |[[Staphylococcus species]] |
||
|ankle |
|ankle |
||
| − | |2-6 weeks |
||
| − | |3 months |
||
| − | |yes; 4-6 weeks IV if not given |
||
|± |
|± |
||
|- |
|- |
||
| ⚫ | |||
| − | |debridement and retention |
||
| ⚫ | |||
|— |
|— |
||
|4-6 weeks |
|4-6 weeks |
||
| Line 104: | Line 84: | ||
| |
| |
||
|- |
|- |
||
| − | |1-stage exchange |
+ | | rowspan="2" |1-stage exchange |
|[[Staphylococcus species]] |
|[[Staphylococcus species]] |
||
|— |
|— |
||
| Line 112: | Line 92: | ||
|± |
|± |
||
|- |
|- |
||
| − | |1-stage exchange |
||
|species other than staphylococci |
|species other than staphylococci |
||
|— |
|— |
||
| Line 277: | Line 256: | ||
|} |
|} |
||
| − | === |
+ | ===Intra-Articular Infusion=== |
| − | * |
+ | *Used in veterinary practice for decades, but only used experimentally in humans |
| − | * |
+ | *Intraoperatively insert two Hickman catheters into the intraarticular space |
| − | ** |
+ | **Two catheters used to ensure that at least one will remain viable for the duration |
| − | * |
+ | *[[Vancomycin]] |
| − | ** |
+ | **May precipitate local inflammatory response necessitating holding it for several days |
==Further Reading== |
==Further Reading== |
||
| Line 291: | Line 270: | ||
[[Category:Bone and joint infections]] |
[[Category:Bone and joint infections]] |
||
| − | [[Category:Infectious diseases]] |
||
Revision as of 11:15, 2 January 2021
Background
Microbiology
- Hip and knee
- Early (<3 months): Staphylococcus aureus (38%), aerobic Gram-negative bacilli (24%), coagulase-negative staphylococci (22%), Enterococcus species (10%), and Streptococcus species (4%), anaerobes including Cutibacterium acnes (3%), culture-negative (10%); 31% are polymicrobial
- Overall: Staphylococcus aureus (27%), coagulase-negative staphylococci (27%), aerobic Gram-negative bacilli (9%), Streptococcus species (8%), anaerobes including Cutibacterium acnes (4%), Enterococcus species (3%), culture-negative (14%); 15% are polymicrobial
- Shoulder: coagulase-negative staphylococci (42%), Cutibacterium acnes (24%), Staphylococcus aureus (18%), aerobic Gram-negative bacilli (10%), others, culture-negative (15%); polymicrobial in 16%
- Elbow: Staphylococcus aureus (42%), coagulase-negative staphylococci (41%), others, culture-negative (5%); polymicrobial in 3%
Epidemiology
- Complicates about 2% of arthroplasty
- 2% of hip and knee arthroplasties
- 1% of shoulder arthroplasties
Pathophysiology
- Bacteria grown on the prosthesis in a biofilm, making it resistant to medical management
Clinical Manifestations
- Most commonly occur within the 3 months after arthroplasty (early); 70% within the first two years
Management
Surgical Therapy
- Ultimately the decision of whether and how to treat surgically rests with the orthopedic surgeon
- Options include:
- Debridement and retention
- One-stage replacement
- Two-stage replacement
- Antibiotic-impregnated cement is often used for the spacer
- Usually vancomycin 2 to 8 g per 40 g cement, or an aminoglycoside
- No clear guidelines for dosing
- No clear evidence of effectiveness, but recommended in all revisions for septic arthritis
- Releases over a period of two to three days
- Usually vancomycin 2 to 8 g per 40 g cement, or an aminoglycoside
Antimicrobial Therapy
| Surgical Management | Species | Location | Duration IV | Total Duration | Adjunctive Rifampin | Chronic Suppressive Thearpy |
|---|---|---|---|---|---|---|
| debridement and retention | Staphylococcus species | knee | 2-6 weeks | 6 months | yes; 4-6 weeks IV if not given | ± |
| hip | 3 months | ± | ||||
| elbow | ± | |||||
| shoulder | ± | |||||
| ankle | ± | |||||
| species other than staphylococci | — | 4-6 weeks | ± | |||
| resection ± reimplantation | — | — | 4-6 weeks | |||
| 1-stage exchange | Staphylococcus species | — | 2-6 weeks | 3 months | yes; 4-6 weeks IV if not given | ± |
| species other than staphylococci | — | 4-6 weeks | 3 months | ± | ||
| amputation with source control | — | — | 24-48 hours | |||
| amputation without source control | — | — | 4-6 weeks |
- IV therapy includes highly bioavailable oral therapy
Intravenous and Highly Bioavailable Oral Therapy
Choice of Antimicrobial
| Species | Preferred Antimicrobials | Alternative Antimicrobials |
|---|---|---|
| Staphylococcus species (oxacillin-susceptible) | nafcillin or cefazolin or ceftriaxone | vancomycin or daptomycin or linezolid |
| Staphylococcus species (oxacillin-resistant) | vancomycin | daptomycin |
| Enterococcus species (penicillin-susceptible) | penicillin G or ampicillin | vancomycin or daptomycin or linezolid |
| Pseudomonas aeruginosa | cefepime or meropenem | ciprofloxacin or ceftazidime |
| Enterobacter species | cefepime | ciprofloxacin |
| Enterobacteriaceae | ampicillin or ceftriaxone or ciprofloxacin | |
| β-hemolytic streptococci | penicillin G or ceftriaxone | vancomycin |
| Cutibacterium acnes | penicillin G or ceftriaxone | clindamycin or vancomycin |
Dosing
| Antimicrobial | Dose |
|---|---|
| ampicillin | 12 g IV q24h continuously or split q4h |
| cefazolin | 1-2 g IV q8h |
| cefepime | 2 g IV q12h |
| ceftazidime | 2 g IV q8h |
| ceftriaxone | 2 g IV q24h |
| ciprofloxacin | 750 mg PO bid |
| ciprofloxacin | 400 mg IV q12h |
| clindamycin | 300-450 mg PO qid |
| clindamycin | 600-900 mg IV q8h |
| daptomycin | 6 mg/kg IV q24h |
| ertapenem | 1 g IV q24h |
| linezolid | 600 mg PO/IV q12h |
| meropenem | 1 g IV q8h |
| nafcillin | 1.5-2 g IV q4-6h |
| penicillin G | 20-24 MU IV q24h continuously or split q4h |
| vancomycin | 15 mg/kg IV q12h |
Chronic Suppressive Therapy
| Microorganism | Preferred treatment | Alternative treatment |
|---|---|---|
| Staphylococcus species (oxacillin-susceptible) | Cephalexin 500 mg PO tid to qid;
Cefadroxil 500 mg PO bid |
Dicloxacillin 500 mg PO tid to qid;
Clindamycin 300 mg PO qid; Amoxicillin-clavulanic acid 500mg PO tid |
| Staphylococcus species (oxacillin-resistant) | TMP-SMX DS 1 tab PO bid;
Doxycycline 100 mg PO bid |
|
| β-hemolytic streptococci | Penicillin V 500 mg PO bid to qid;
Amoxicillin 500 mg PO tid |
Cephalexin 500 mg PO tid to qid |
| Enterococcus species (penicillin-susceptible) | Penicillin V 500 mg PO bid to qid;
Amoxicillin 500 mg PO tid |
|
| Pseudomonas aeruginosa | Ciprofloxacin 250-500 mg PO bid | |
| Enterobacteriaceae | TMP-SMX DS 1 tab PO bid | Beta-lactam, if susceptible |
| Cutibacterium | Penicillin V 500 mg PO bid to qid;
Amoxicillin 500 mg PO tid |
Cephalexin 500 mg PO tid to qid;
Doxycycline 100 mg PO bid |
Intra-Articular Infusion
- Used in veterinary practice for decades, but only used experimentally in humans
- Intraoperatively insert two Hickman catheters into the intraarticular space
- Two catheters used to ensure that at least one will remain viable for the duration
- Vancomycin
- May precipitate local inflammatory response necessitating holding it for several days
Further Reading
- Prosthetic Joint Infection. Clin Micro Rev. 2014;27(2):302-345. doi: 10.1128/CMR.00111-13
- Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guidelines by the IDSA. Clin Infect Dis. 2013;56(1):e1-25. doi: 10.1093/cid/cis803
References
- ^ Louis Bernard, Cédric Arvieux, Benoit Brunschweiler, Sophie Touchais, Séverine Ansart, Jean-Pierre Bru, Eric Oziol, Cyril Boeri, Guillaume Gras, Jérôme Druon, Philippe Rosset, Eric Senneville, Houcine Bentayeb, Damien Bouhour, Gwenaël Le Moal, Jocelyn Michon, Hugues Aumaître, Emmanuel Forestier, Jean-Michel Laffosse, Thierry Begué, Catherine Chirouze, Fréderic-Antoine Dauchy, Edouard Devaud, Benoît Martha, Denis Burgot, David Boutoille, Eric Stindel, Aurélien Dinh, Pascale Bemer, Bruno Giraudeau, Bertrand Issartel, Agnès Caille. Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection. New England Journal of Medicine. 2021;384(21):1991-2001. doi:10.1056/nejmoa2020198.
- ^ Werner Zimmerli, Parham Sendi. Role of Rifampin against Staphylococcal Biofilm InfectionsIn Vitro, in Animal Models, and in Orthopedic-Device-Related Infections. Antimicrobial Agents and Chemotherapy. 2018;63(2):e01746-18. doi:10.1128/aac.01746-18.
- ^ James B. Doub, Emily L. Heil, Afua Ntem-Mensah, Renaldo Neeley, Patrick R. Ching. Rifabutin Use in Staphylococcus Biofilm Infections: A Case Series. Antibiotics. 2020;9(6):326. doi:10.3390/antibiotics9060326.
